Open Innovation Success Stories
Hear from our collaborators on their experience of partnering with us
We’ve enabled over 400 collaborations since 2014.
View examples of how collaboration between industry and academia can bring mutual benefits to external researchers and AstraZeneca, as well as contribute new insights to diverse areas of science.
Bart Vanhaesebroeck, Professor of Medical Sciences, University College London, UK
Professor Vanhaesebroeck shares his experience partnering with AstraZeneca for over eight years, and the importance of open innovation to investigate ambitious research topics in drug discovery.
Cecilia Rodrigues, Faculty of Pharmacy, University of Lisbon, Portugal
Professor Rodrigues shares her experience of collaborating through Open Innovation to identify active compounds for a known cell death target using AstraZeneca’s phenotypic screening library.
Filipe Pereira, Faculty of Medicine, Lund University, Sweden
Professor Pereira discusses his successful proposal to identify small molecules that could substitute for transcription factors in cellular reprogramming, using AstraZeneca’s extensive screening library and proficiency in data analysis.
Ana Tiganescu, Research Fellow, University of Leeds, UK
Dr Tiganescu shares highlights from her long-standing collaboration with Open Innovation, exploring a small molecule from AstraZeneca’s compound library for its potential in wound healing and supporting translation from bench to bedside.
Dahl Winters, Chief Technology Officer, DeepScience Ltd, US
Ms Winters discusses the DeepScience collaboration with Open Innovation to advance technology solutions, product design and testing to bring about positive patient outcomes.